Clinical Trial Update: A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of nalirifoX (nanoliposomal irinotecan) with radiation therapy for pancreatic ductal adenocarcinoma is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Onivyde (irinotecan hydrochloride liposome injection)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: RECRUITING